Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model.
Immunology
Virology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
19 Aug 2022
19 Aug 2022
Historique:
received:
10
12
2021
revised:
15
03
2022
accepted:
28
06
2022
pubmed:
12
7
2022
medline:
12
7
2022
entrez:
11
7
2022
Statut:
ppublish
Résumé
Treatment with neutralizing monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contributes to COVID-19 management. Unfortunately, SARS-CoV-2 variants escape several of these recently approved mAbs, highlighting the need for additional discovery and development. In a convalescent patient with COVID-19, we identified six mAbs, classified in four epitope groups, that potently neutralized SARS-CoV-2 D614G, beta, gamma, and delta infection
Identifiants
pubmed: 35813873
doi: 10.1016/j.isci.2022.104705
pii: S2589-0042(22)00977-4
pmc: PMC9250818
doi:
Types de publication
Journal Article
Langues
eng
Pagination
104705Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
The authors filed two patent applications: EP21206787.0 and EP21216594.8.
Références
Cell. 2021 Apr 1;184(7):1821-1835.e16
pubmed: 33667349
Cell. 2020 Nov 12;183(4):1058-1069.e19
pubmed: 33058755
Nat Med. 2021 Aug;27(8):1379-1384
pubmed: 34127854
Science. 2020 Aug 21;369(6506):1014-1018
pubmed: 32540904
Science. 2020 Nov 27;370(6520):1110-1115
pubmed: 33037066
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
Hum Gene Ther. 2019 Nov;30(11):1431-1443
pubmed: 31382777
Nat Commun. 2022 Nov 4;13(1):6644
pubmed: 36333374
Front Immunol. 2020 Dec 18;11:614256
pubmed: 33391285
Nat Commun. 2021 Jul 7;12(1):4196
pubmed: 34234131
Nature. 2021 May;593(7857):136-141
pubmed: 33706364
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
Science. 2020 Aug 21;369(6506):1010-1014
pubmed: 32540901
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
Nat Protoc. 2014 Jan;9(1):171-81
pubmed: 24385147
Oncotarget. 2018 Feb 6;9(17):13623-13636
pubmed: 29568382
Nature. 2021 Feb;590(7845):320-325
pubmed: 33260195
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
Cell. 2021 Jun 10;184(12):3086-3108
pubmed: 34087172
Biochem Biophys Res Commun. 2021 Aug 20;566:135-140
pubmed: 34119826
Emerg Microbes Infect. 2020 Dec;9(1):1523-1533
pubmed: 32579067
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
Nat Rev Immunol. 2021 Jun;21(6):382-393
pubmed: 33875867
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
Nat Microbiol. 2020 Oct;5(10):1185-1191
pubmed: 32908214
Cell. 2021 Apr 1;184(7):1804-1820.e16
pubmed: 33691139
J Virol. 1997 Dec;71(12):9608-17
pubmed: 9371625
Cell Rep. 2022 May 17;39(7):110812
pubmed: 35568025
N Engl J Med. 2021 Jun 10;384(23):2212-2218
pubmed: 33882219
Signal Transduct Target Ther. 2022 Jan 28;7(1):28
pubmed: 35091532
Science. 2020 Mar 13;367(6483):1264-1269
pubmed: 32165588
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Cell Rep Med. 2021 Mar 16;2(3):100218
pubmed: 33649747
Int J Infect Dis. 2021 Sep;110:232-234
pubmed: 34271202
Cell. 2021 Apr 29;184(9):2348-2361.e6
pubmed: 33730597
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Cell. 2021 Mar 4;184(5):1171-1187.e20
pubmed: 33621484
Science. 2020 Nov 20;370(6519):950-957
pubmed: 32972994
J Mol Biol. 2021 Sep 3;433(18):167155
pubmed: 34273397
Hum Gene Ther. 2021 Oct;32(19-20):1200-1209
pubmed: 34482757
Biotechniques. 2006 Apr;40(4):469-70, 472, 474 passim
pubmed: 16629394
Nat Commun. 2020 Nov 17;11(1):5838
pubmed: 33203860
Front Microbiol. 2021 Jun 25;12:698944
pubmed: 34248922
EBioMedicine. 2021 Jun;68:103403
pubmed: 34049240
Nat Med. 2021 Apr;27(4):717-726
pubmed: 33664494
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
J Transl Med. 2017 Jun 7;15(1):131
pubmed: 28592330
Sci Rep. 2022 Mar 18;12(1):4683
pubmed: 35304531
Ther Adv Infect Dis. 2021 Jun 18;8:20499361211024372
pubmed: 34211709
Proc Natl Acad Sci U S A. 2020 Oct 27;117(43):26955-26965
pubmed: 33037151